{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-006962","form_type":"8-K","ticker":"PMDI","cik":"0000806517","company_name":"PSYCHEMEDICS CORP","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.053331+00:00","generated_at":"2026-06-08T08:12:45.143021+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Psychemedics Q3 revenue $5.7M (-12% YoY); net loss widens to $2.1M","bullets":["Revenue $5.7M vs $6.5M YoY; net loss $(2.1M) or $(0.36)/diluted share vs $(0.02) loss.","Gross margin improved to 37% from 36%, cost programs partly offset revenue decline.","Operating expenses up 18% due to legal/settlement fees, CEO transition, and consulting.","Non-cash tax charge of $0.7M on deferred tax assets deemed unrealizable.","Restructuring initiated to align costs; new CRO Shannon Shoemaker leading go-to-market changes."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-006962","json":"https://secwatch.observer/filing/0001171843-23-006962.json","markdown":"https://secwatch.observer/filing/0001171843-23-006962.md","text":"https://secwatch.observer/filing/0001171843-23-006962.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/806517/000117184323006962/0001171843-23-006962-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/806517/000117184323006962/f8k_110923.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T08:12:45.143021+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"48e94d43c7406c2cb776a725c066b454c1622b86","claim":"PSYCHEMEDICS CORP reported the third quarter ended September 30, 2023 results: revenue $5.7 million, net income $(2.1 million), EPS $(0.36) per diluted share.","evidence_excerpt":"The Company’s revenue for the quarter ended September 30, 2023, was $5.7 million versus $6.5 million for the quarter ended September 30, 2022, a decrease of 12%. Net loss for the quarter ended September 30, 2023, was $(2.1 million) or $(0.36) per diluted share, versus net loss of $(97,000) or $(0.02) per diluted share, for the comparable period last year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/806517/000117184323006962/0001171843-23-006962-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$5.7 million"},{"label":"Net income","value":"$(2.1 million)"},{"label":"EPS","value":"$(0.36) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}